Last reviewed · How we verify

Staining method — Treatment Landscape & Competitive Intelligence

Staining method (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Staining method, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tissueblue BRILLIANT BLUE G Dutch Ophthalmic Disclosing Agent [EPC] P2X purinoceptor 7 2019-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Dutch Ophthalmic · 1 drug in Staining method

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Staining method:

Cite this brief

Drug Landscape (2026). Staining method — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staining-method. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing